Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Structural dynamics of Ras proteins contribute to their activity in signal transduction cascades. Directly targeting Ras proteins with small molecules may rely on movement of a conserved structural motif, switch II. To understand Ras signaling and advance Ras targeting strategies, experimental methods to measure Ras dynamics are required. Here we demonstrate the utility of hydrogen-deuterium exchange mass spectrometry to measure Ras dynamics by studying representatives from two branches of the Ras superfamily, Ras and Rho. A comparison of differential deuterium exchange between active (GMPPNP-bound) and inactive (GDP-bound) proteins revealed differences between the families, with the most notable differences occurring in the phosphate-binding loop and switch II. The P-loop exchange signature correlated with switch II dynamics observed in molecular dynamics simulations focused on measuring main chain movement. Hydrogen-deuterium exchange provides a means of evaluating Ras protein dynamics which may be useful for understanding mechanisms of Ras signaling, including activated signaling of pathologic mutants, and for targeting strategies that rely on protein dynamics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 3×
“Recent advances to target specific Ras mutants directly, such as K-Ras G12C with covalent inhibitors, have generated considerable optimism that direct Ras therapy may be possible [6, 32, 33].”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Such Ras mutations are present in 20–30% of all human tumor types, and over 90% of tumors for certain diseases such as pancreatic cancer [6, 31].”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 3×
“Recent advances to target specific Ras mutants directly, such as K-Ras G12C with covalent inhibitors, have generated considerable optimism that direct Ras therapy may be possible [6, 32, 33].”
BackgroundThe Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
A new bioinformatics analysis tools framework at EMBL-EBI
Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J., & Lopez, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq313 · Cited by 1,846 · cited 4×
“The crystal structures of these proteins are organized using a phylogenetic tree, generated using Clustal Omega in conjunction with DrawTree [64, 65], which is shown in the middle.”
MethodInfluentialHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
The structural basis of the activation of Ras by Sos
Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799 · cited 1×
“This exposes the nucleotide binding site through interactions with the switch domains, allowing GDP to escape [14].”
BackgroundBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 7×
“Colicelli J. Human RAS superfamily proteins and related GTPases.”
BackgroundResultInfluentialSelf-citationSelective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Self-citationDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188 · cited 1×
“As investigators have searched for targetable vulnerabilities in signal transduction pathways mediated by oncogenic mutant Ras, it has become clear that protein dynamics contribute significantly to the functional output of subsets of Ras mutations, and that understanding these differences may lead to new therapeutic o…”
Background
Cited by
Masson, G. R., Burke, J. E., Ahn, N. G., Anand, G. S., Borchers, C., Brier, S., Bou-Assaf, G. M., Engen, J. R., Englander, S. W., Faber, J., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0459-y · Cited by 729
Self-citationJames, E. I., Murphree, T. A., Vorauer, C., Engen, J. R., & Guttman, M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00279 · Cited by 305
Self-citationKRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
“GTP loading was verified by back extraction of nucleotide using 6M urea and evaluation of nucleotide peaks by HPLC using an ion-exchange column as described previously (Harrison et al., 2016).”
MethodTissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Self-citationExpanding the scope of electrophiles capable of targeting K-Ras oncogenes
McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97
Metadata
- Authors
- Harrison, R. A., Lu, J., Carrasco, M., Hunter, J., Manandhar, A., Gondi, S., Westover, K. D., & Engen, J. R.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 428
- Issue
- 23
- Pages
- 4723-4735
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W2536408153
- Cited by
- 37
- References
- 14
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.